Pulmonary Arterial Hypertension (PAH) II: Therapeutic Strategies By THE 8TH ANNUAL INTERNATIONAL HAWlabwebsite20170701Jan 7, 20191 min readUpdated: Jan 9, 2019By THE 8TH ANNUAL INTERNATIONAL HAWAII SYMPOSIUM ON DIAGNOSTIC AND THERAPEUTIC MODALITIES IN HEART FAILURE
Empagliflozin Attenuates Pulmonary Arterial Remodeling Through Peroxisome Proliferator-Activated Receptor Gamma Activation.
Comments